SEROTONIN NOREPINEPHRINE INHIBITOR MARKET ANALYSIS

Global serotonin norepinephrine inhibitor market was valued at USD 6.29 bn in 2023 and is expected to exhibit a compounded annual growth rate (CAGR) of 4.2% from 2022 to 2030. By 2030, the market is estimated to reach USD 8.41 bn.

Increasing prevalence of mental health disorders such as depression and anxiety, increasing awareness about mental health, and the availability of effective treatment options is expected to drive the market growth of the global serotonin norepinephrine inhibitors market. However, the market is also restrained by factors such as high cost, limited efficacy, and side effects associated with serotonin norepinephrine inhibitors. For instance, on March 31 2023, according to data published by World Health Organization(WHO), an estimated 3.8% of the population experiences depression, including 5% of adults (4% among men and 6% among women), and 5.7% of adults are older than 60 years. Approximately 280 Mn people in the world have depression which is 50% more common among women than among men.

Global Serotonin Norepinephrine Inhibitor Market- Regional Insights

• North America: North America is expected to dominate the serotonin norepinephrine inhibitor market due to the high prevalence of depression and anxiety disorders in the region. The presence of major pharmaceutical companies, favorable government initiatives, and increasing awareness about mental health issues are expected to further drive the market growth in this region. Moreover, increasing prevalence of diabetes in the region is expected to drive the growth of global serotonin norepinephrine inhibitor market over the forecast period. For instance, in 2022, according to data published by Panorama of Diabetes in the Americas, it is estimated that globally, the age-standardized prevalence of raised fasting glucose/diabetes has nearly doubled over 30 years, from 4.7% in 1980 to 8.5% in 2014, which reflects an increase in the number of people living with diabetes from 108 Mn  to 422 Mn . In the Americas, the age-standardized prevalence of raised fasting blood glucose (≥7.0 mmol/L) is estimated as 8.3%, with only a small difference between men (8.5%) and women (8.1%).
• Europe: Europe is also expected to witness significant growth in the serotonin norepinephrine inhibitor market due to the increasing prevalence of depression and anxiety disorders and the presence of major pharmaceutical companies. Increasing mental health awareness campaign in the region is expected to further boost the market growth in this region. For instance, Mental Health Europe (MHE) announced its fourth edition of the European Mental Health Week from May 22, 2023 to May 28, 2023. The goal of this year’s Awareness Week was  to increase understanding and learning about mental health in our communities, schools, workplaces, and at home so that everyone can thrive and flourish at every stage of life. 
• Asia Pacific: Asia Pacific region is expected to witness significant growth in the serotonin norepinephrine inhibitor market due to the increasing awareness about mental health issues and the increasing demand for effective treatments. The region has a large population base and a high prevalence of depression and anxiety disorders, which is expected to drive the demand for serotonin norepinephrine inhibitors.

Figure 1. Global Serotonin Norepinephrine Inhibitor Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst View:

The global serotonin norepinephrine inhibitor market is expected to witness steady growth over the forecast period driven by rising prevalence of depression worldwide. Growing geriatric population who are more susceptible to develop depression and other neurological disorders will further aid the market expansion. In addition, late-stage pipeline drugs entering the market and approval of newer indications for existing drugs are likely to open new avenues for market players. However, patent expiries of major drugs may impede the market growth to some extent. North America presently dominates the global market and is expected to continue its dominance led by growing adoption of SNRIs in the US for treatment of depression. Favorable reimbursement policies for mental health are boosting the market in the region. Europe is also expected to offer lucrative opportunities for market participants during the forecast period due to rising mental health expenditure.

Asia Pacific is anticipated to emerge as the fastest growing region in the global serotonin norepinephrine inhibitor market. Increasing focus of leading SNRI manufacturers on developing Asian markets by launching affordable generic drugs will significantly drive the regional market. Moreover, rising geriatric population, growing mental health awareness, and improving healthcare infrastructure are some key factors expected to augment the market growth in Asia Pacific.

Global Serotonin Norepinephrine Inhibitor Market Drivers:

• Increasing prevalence of depression and anxiety disorders: The growing prevalence of depression and anxiety disorders worldwide is a major driver of the global serotonin norepinephrine inhibitor market. Serotonin norepinephrine inhibitors are commonly used to treat these disorders, and the increasing demand for these medications is expected to drive the market growth. For instance, on June 16, 2023 according to data published by Centers for Disease Control and Prevention (CDC), during 2020, the age-standardized prevalence of depression among adults was 18.5%. Among the states, the age-standardized prevalence of depression ranged from 12.7% to 27.5%; most of the states with the highest prevalence were in the Appalachian and southern Mississippi Valley regions.
• Availability of new and improved drugs: The availability of new and improved global serotonin norepinephrine inhibitors is expected to drive the market growth. The development of new drugs with improved efficacy and fewer side effects is expected to increase the demand for these medications.
• Growing awareness about mental health issues: The growing awareness about mental health issues and the importance of seeking treatment is expected to drive the growth of the global serotonin norepinephrine inhibitor market. The increasing efforts by governments, healthcare providers, and advocacy groups to raise awareness about mental health issues are expected to boost the demand for these medications.
• Favorable government initiatives: The favorable government initiatives, such as reimbursement policies and healthcare reforms, are expected to drive the market growth of the global serotonin norepinephrine inhibitor. The availability of these medications at affordable prices is expected to increase the demand for these medications.

Global Serotonin Norepinephrine Inhibitor Market Opportunities:

• Increasing adoption of telemedicine: The increasing adoption of telemedicine is expected to drive the growth of the global serotonin norepinephrine inhibitor market. The availability of telemedicine services allows patients to access healthcare services from remote locations, which is expected to increase the demand for these medications. For instance, according to data published by The RAND Corporation, a research organization, telehealth services for common mental health problems increased 16 to 20 times in the first year of the COVID-19 pandemic.
• Personalized medicine: The development of personalized medicine is expected to drive the growth of the global serotonin norepinephrine inhibitor market. The development of drugs that can be tailored to the individual needs of patients is expected to increase the efficacy and safety of these medications, which is expected to increase the demand for these medications.
• Combination therapy: The combination therapy of serotonin norepinephrine inhibitors with other drugs is expected to drive the market growth of the global serotonin norepinephrine inhibitor market. The combination therapy can improve the efficacy of these medications and reduce the side effects, which are expected to increase the demand for these medications.
• Increased focus on mental health: The increased focus on mental health issues and the importance of seeking treatment is expected to drive the growth of the global serotonin norepinephrine inhibitor market. The increasing efforts by governments, healthcare providers, and advocacy groups to raise awareness about mental health issues are expected to boost the demand for these medications.

Global Serotonin Norepinephrine Inhibitor Market Trends:

• Shift towards generic drugs: The growing trend towards generic drugs is expected to impact the global serotonin norepinephrine inhibitor market. The increasing use of generic drugs is expected to increase the competition in the market, which is expected to reduce the prices of these medications.
• Increasing use of selective serotonin reuptake inhibitors (SSRIs): The increasing use of SSRIs is expected to impact the global serotonin norepinephrine inhibitor market. SSRIs are commonly used to treat depression and anxiety disorders and are increasingly preferred over serotonin norepinephrine inhibitors due to their lower cost and fewer side effects. In 2020, according to data published by the Centers for Disease Control and Prevention (CDC), an estimated 21.6% of the U.S. adult population experiences mental illness. This suggests a massive patient pool that may require multiple lines of treatment before finding an effective option.
• Technological advancements: The technological advancements in the development of new drugs and drug delivery systems are expected to impact the global serotonin norepinephrine inhibitor market. The development of new drugs with improved efficacy and fewer side effects and the development of new drug delivery systems that can enhance the efficacy and safety of these medications are expected to drive the market growth of the global serotonin norepinephrine inhibitor market.
• Growing focus on natural remedies: The growing focus on natural remedies for mental health issues is expected to impact the global serotonin norepinephrine inhibitor market. The increasing demand for natural remedies, such as herbal supplements and mindfulness-based therapies, is expected to reduce the demand for these medications.

Global Serotonin Norepinephrine Inhibitor Market Restraints:

• Side effects: The side effects associated with the use of serotonin norepinephrine inhibitors, such as nausea, dizziness, and headaches, are a major restraint on the market growth.  The side effects can limit the use of these medications and reduce patient’s compliance.
• High cost: The high cost of serotonin norepinephrine inhibitors is a major restraint on the market growth. The high cost of these medications can limit their use, especially in developing countries.
• Limited efficacy: The limited efficacy of serotonin norepinephrine inhibitors in some patients is a major restraint on the growth of the market. The medications may not work for all patients, and some patients may require other forms of treatment.

Counterbalance: The key market players must ensure that the side effects, high costs, and the limited efficacy associated with the serotonin norepinephrine inhibitors is neglible during the manufacturing process of these medications.

Figure 2. Global Serotonin Norepinephrine Inhibitor Market Share (%), By Application, 2023

To learn more about this report, request a free sample copy

Recent Developments

Acquisition and partnerships

• In 2018, Takeda Pharmaceutical Company, a multinational pharmaceutical company, and Lundbeck, a pharmaceutical company, announced a partnership to co-develop and co-commercialize two new drugs for the treatment of mood disorders, including a serotonin norepinephrine inhibitor.
• In 2020, Eli Lilly, a pharmaceutical company, and Boehringer Ingelheim, a pharmaceutical company, announced a partnership to co-develop and co-commercialize a new drug for the treatment of major depressive disorder, which includes a serotonin norepinephrine inhibitor.
• In 2015, Allergan, a pharmaceutical company and AstraZeneca, a multinational pharmaceutical and biotechnology company, announced a partnership to co-develop and co-commercialize a new drug for the treatment of major depressive disorder, which includes a serotonin norepinephrine inhibitor.

Top Companies in Global Serotonin Norepinephrine Inhibitor Market

• Pfizer Inc.
• Eli Lilly and Company
• Allergan Plc.
• AstraZeneca Plc.
• Forest Laboratories Inc.
• Johnson & Johnson
• Lundbeck A/S
• Merck & Co., Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Wyeth Pharmaceuticals Inc.
• Zydus Cadila Healthcare Ltd.

Definition: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are a class of medications which are commonly used to treat mental health conditions such as major depressive disorder (MDD), generalized anxiety disorder (GAD), and certain types of chronic pain. SNRIs work by inhibiting the reuptake of two neurotransmitters, serotonin and norepinephrine, in the brain. By blocking the reuptake process, SNRIs increase the levels of serotonin and norepinephrine, which can help regulate mood, improve emotional well-being, and reduce pain perception.